莫西沙星联合补充阴道用益生菌治疗需氧菌性阴道炎的疗效及对复发的影响

目的对莫西沙星联合补充益生菌治疗需氧菌性阴道炎（AV）的疗效及对复发的影响进行探讨。 方法以2020年2月~2021年3月枣庄市妇幼保健院妇科及生殖科、滕州市妇幼保健院妇科及生殖科就诊、经诊断为单纯需氧菌阴道炎的患者124例进行回顾性研究,根据治疗方法不同分为：莫西沙星治疗组共65例,莫西沙星治疗组联合阴道用乳杆菌胶囊59例。比较治疗前后2组患者pH值、AV评分及其白介素-8（IL-8）、白介素-1β（IL-1β）炎症指标。同时,比较2组患者症状情况缓解情况以及复发情况。 结果莫西沙星组和联合用药组2组治疗后的pH值、AV评分、IL-8、IL-1β均低于治疗前,其中联合用药组显著优于莫西沙星组,差异具有统计学意义（P＜0.05）。治疗后,2组患者具有临床症状的患者数量均下降,但2组有症状患者的比例差异无统计学意义（P＞0.05）。联合用药组治疗有效率为83.05%,显著高于莫西沙星组的67.69%（P＜0.05）。第二次随访时,莫西沙星组患者有7例发生了复发,联合用药组患者共2例发生了复发,2组比较复发率相近,差异无统计学意义（P＞0.05）。 结论莫西沙星联合使用阴道用益生菌胶囊可有效治疗需氧菌阴道炎,可降低AV评分和pH值,改善临床症状,为需氧菌阴道炎的治疗提供了新的思路。

Moxifloxacin combined with Lactobacillus capsules for vaginal use for treatment of aerobic vaginitis: efficacy and influence on recurrence

ObjectiveTo evaluate the efficacy of moxifloxacin combined with Lactobacillus capsules for vaginal use in the treatment of aerobic vaginitis (AV) and its effect on relapse. MethodsA total of 124 patients diagnosed with aerobic vaginitis from February 2020 to March 2021 at the Departments of Gynecology and Reproduction, Maternity and Child Health Care of Zaozhuang, and the Departments of Gynecology and Reproduction, Maternity and Child Health Care of Tengzhou were included retrospectively. The patients were treated with either moxifloxacin alone (n=56) or moxifloxacin combined with Lactobacillus capsules for vaginal use. The pH value, AV score, and the inflammatory indicators interleukin-8 (IL-8) and interleukin-1β (IL-1β) were compared between the two patient groups before and after treatment. The remission of symptoms and recurrence were also compared between the two groups. ResultsAfter treatment, the pH value, AV score, and IL-8 and IL-1β levels were lower the values before treatment in both groups, and these indexes were significantly better in the combination group than in the moxifloxacin alone group (P<0.05). After treatment, the number of patients with clinical symptoms decreased in both groups, but no significant difference in the proportion of symptomatic patients was noted between the two groups (P＞0.05). The effective rate of the combined treatment group (83.05%) was significantly higher than that of the moxifloxacin alone group (67.69%; P＜0.05). At the second follow-up, five patients in the moxifloxacin group and four in the combination group had similar recurrence rates (P＞0.05). ConclusionMoxifloxacin combined with Lactobacillus capsules for vaginal use can effectively treat aerobic vaginitis, reduce AV score and pH value, and improve clinical symptoms, providing a new avenue for the treatment of aerobic vaginitis.